Hemophilia B

The US Food and Drug Administration recently approved a new treatment option for patients with hemophilia B.

After successful results from a pivotal clinical trial, a new dosage for an integrase inhibitor was approved by the FDA.

The US Food and Drug Administration has approved a new generic option for the treatment of attention-deficit/hyperactivity disorder.

The FDA has broadened the approval of a non-small cell lung cancer drug, previously approved in 2014.

The FDA has broadened the approval of a non-small cell lung cancer drug, previously approved in 2014.

The FDA has broadened the approval of a non-small cell lung cancer drug, previously approved in 2014.

After successful testing, a new treatment for rheumatoid arthritis has been approved by the US Food and Drug Administration.

After successful testing, a new treatment for rheumatoid arthritis has been approved by the US Food and Drug Administration.

After successful testing, a new treatment for rheumatoid arthritis has been approved by the US Food and Drug Administration.

The FDA has approved the first drug specifically approved for the treatment of a type of vasculitis with previously limited treatment options.